The pharmaceutical corporation Pfizer announced Tuesday that its experimental weight loss jab showed solid results when taken monthly during an ongoing mid-stage clinical trial.
Adults with obesity using the GLP-1 receptor agonist class drug known as “PF-08653944” shed up to 12.3 percent of their body weight compared with a placebo drug after 28 weeks, the New York City-based drugmaker said in a statement.
